Microbiome-driven PKs: redefining drug metabolism beyond host enzymes

We propose that the gut microbiome should be recognized as a 'fifth pillar' of PKs. This shift in perspective is crucial for advancing personalized medicine. In this new model, a 'PK profile card' integrating microbial, genomic, and clinical data will help guide dosing. We anticipate microbiome analysis to become a standard clinical tool to optimize drug efficacy and safety.

Authors

Amina Džidić-Krivić
Marc Labriffe (ORCID: https://orcid.org/0000-0001-5840-8904)
Hing Yee Sy (ORCID: https://orcid.org/0000-0002-0298-1696)
Kristina Pilipović
Yun Wah Lam
Lejla Alić (ORCID: https://orcid.org/0000-0003-0197-0837)
Slobodan Jankovic
Andrej Belančić
Almir Fajkić

Institutions

University of Sarajevo (BA)
University of Kragujevac (RS)
University of Rijeka (HR)
City University of Hong Kong (HK)
University of Zenica (BA)
Centre Hospitalier Universitaire de Limoges (FR)
Université de Limoges (FR)

Publication Details

Journal: Expert Opinion on Drug Metabolism & Toxicology
Published: 2026-01-02
DOI: https://doi.org/10.1080/17425255.2026.2631415
Primary Topic: Gut microbiota and health
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Microbiome-driven PKs: redefining drug metabolism beyond host enzymes

Amina Džidić-Krivić, Marc Labriffe, Hing Yee Sy, Kristina Pilipović et al.

Jan 2, 2026

Expert Opinion on Drug Metabolism & Toxicology

Gut microbiota and health

article

Microbiome-driven PKs: redefining drug metabolism beyond host enzymes

Amina Džidić-Krivić, Marc Labriffe, Hing Yee Sy, Kristina Pilipović, Yun Wah Lam, Lejla Alić, Slobodan Jankovic, Andrej Belančić, Almir Fajkić

January 2, 2026article en

Abstract

We propose that the gut microbiome should be recognized as a 'fifth pillar' of PKs. This shift in perspective is crucial for advancing personalized medicine. In this new model, a 'PK profile card' integrating microbial, genomic, and clinical data will help guide dosing. We anticipate microbiome analysis to become a standard clinical tool to optimize drug efficacy and safety.

Expert Opinion on Drug Metabolism & ToxicologyVol. 22(1)

University of Sarajevo (BA), University of Kragujevac (RS), University of Rijeka (HR), City University of Hong Kong (HK), University of Zenica (BA), Centre Hospitalier Universitaire de Limoges (FR), Université de Limoges (FR)

Good health and well-being

Openalex Percentile: Top 54%

Gut microbiota and health

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Microbiome-driven PKs: redefining drug metabolism beyond host enzymes — Amina Džidić-Krivić, Marc Labriffe, et al. · Expert Opinion on Drug Metabolism & Toxicology (2026) | TGRS Research Map | TGRS